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Abstract
Inhibition of Extracellular Matrix degradation by nitric oxide (NO) induces cardiac protection
against coronary ischemia/reperfusion (IR). Glycosylation of Extracellular MatrixMetallo-
proteinase Inducer (EMMPRIN) stimulates enzymatic activation of matrixmetalloprotei-
nases (MMPs) in the heart, although the mechanisms leading to EMMPRIN glycosylation
are poorly understood.We sought to determine if NOmay induce cardiac protection by pre-
venting glycosylation of EMMPRIN in a mousemodel of IR. Here we found that Caveolin-3
binds to low glycosylated EMMPRIN (LG-EMMPRIN) in cardiac cells and in the hearts of
healthy mice, whereas IR disrupted the complex in nitric oxide synthase 2 (NOS2) knockout
(KO) mice. By contrast, the binding was partially restoredwhenmice were fed with an NO
donor (DEA-NO) in the drinkingwater, showing a significant reduction on infarct size
(NOS2KO: 34.6±5 vs NOS2KO+DEA-NO: 20.7±9), in expression of matrixmetalloprotei-
nases, and cardiac performancewas improved (left ventricular ejection fraction (LVEF).
NOS2KO: 31±4 vsNOS2KO+DEA-NO: 46±6). The role of Caveolin-3/EMMPRIN in NO-
mediated cardiac protectionwas furtherassayed in Caveolin-3 KO mice, showing no signifi-
cant improvement on infarct size (Caveolin-3 KO: 34.8±3 vs Caveolin-3 KO+DEA-NO:33.7
±5), or in the expression of MMPs, suggesting that stabilization of the complex Caveolin-3/
LG-EMMPRINmay play a significant role in the cardioprotective effect of NO against IR.
Introduction
MMPs are proteolytic degrading enzymes that cleave extracellularmatrix (ECM) components.
In the heart, MMP enzymatic activation induces cardiac myocyte necrosis, heart failure, and
abnormal ventricular remodeling [1]. The ExtracellularMatrix MetalloPRoteinase INducer
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EMMPRIN (CD147, Basigin) regulates the expression of several MMPs, including MMP-2 and
MMP9, and it plays a pivotal role in the inflammatory response to ischemia in monocytes and
cardiac cells [2, 3].
Caveolae are cholesterol and sphingolipid enriched small vesicles present in the cell mem-
branes of several cell types, including cardiac myocytes [4]. Caveolae harbor many signaling
pathways, in which caveolins play a dual role as structural, and regulatory elements through
protein-protein interaction with resident caveolar proteins [5]. The expression patterns of
Caveolin -1, and -2, are distinct from that of Caveolin-3, the later limited to smooth, skeletal
and cardiac muscle [6].
The role of caveolins in the NO signaling pathway has been well documented. In the cardio-
vascular system Caveolin-1 and -3 interact with NOS3, resulting in eNOS inactivity [7]. How-
ever, in response to IR they both induce cardiac protection by different mechanisms, including
those leading to NO production [8, 9].
EMMPRIN contains two extracellular Ig domains. The first domain is required for MMP
activation in high-glycosylated EMMPRIN oligomers at the cell surface of many cell types [10].
We and others found that NO prevents the expression of EMMPRIN in cardiac myocytes [3,
11], but the precise role at the protein level is yet unknown. The second Ig domain of EMM-
PRIN is required for interaction with other proteins. Low glycosylated EMMPRIN (LG-EMM-
PRIN) binds to Caveolin-1, and prevents EMMPRIN glycosylation and self-aggregation, a
requirement to induce MMP activation [10].
In the present work we investigated the contribution of NO in the interaction between




Evans blue, Triphenyl tetrazolium chloride (TTC), doxycycline and interleukin-18 (IL-18)
were from Sigma (Spain). Horse radish peroxidase (HRP)-conjugated anti-mouse secondary
antibody and liquid 3,3'-diaminobenzidine (DAB) substrate were from Dako (Carpinteria,
CA). Anti MMP-9, anti Caveolin-3, anti- and FITC-conjugated secondary antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA). HRP-conjugated anti-rabbit secondary anti-
body, was from Sigma-Aldrich.Amersham ECL detection kit was from GE (GE Healthcare
Life Sciences, Spain). Centrifugation concentrators were from Sartoriuos (Fischer Scientific,
Spain).
Animals
NOS2 null mice, Caveolin-3 null mice, and the corresponding wild-type controls were housed
in our animal facilities in isolated rooms. Animal studies have been performed in accordance
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amend-
ments. All animal procedures were approved by the National Research Ethics Committee and
conformed to EU Directive 86/609/EEC and recommendation 2007/526/EC regarding the pro-
tection of animals used for experimental and other scientific purposes (enacted under Spanish
law 1201/2005).
Cells
The HL1B cell line was kindly donated by Dr. Antonio Bernad. Cells were cultured in T150
flasks with Claycomb media, supplemented with 10% FCS, 0.1mM norepinephrine, 1.5 mM L-
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glutaminie and 50 units/ml penicillin-streptomycin. After confluence, cells were split into 10
cm dishes for experimentation.
Animal model of Ischemia/Reperfusion
Ischemia was induced by coronary artery ligation. Twelve-week- old mice were intraperitone-
ally anesthetized with ketamine/xylazine (100 and 10 mg/kg, respectively), intubated with a
1-mm steel tube, and ventilated (2ml, 80 strokes/min). The thorax was opened between the sec-
ond and the third ribs and widenedwith the aid of a mouse retractor. The pericardium was
opened and the left anterior descending (LAD) coronary artery was occluded for 30 min close
to its bifurcation with a 6–0 silk suture. Reperfusionwas performed by releasing suture, 30
minutes after LAD occlusion. The chest was closed, negative pressure was reestablished, and
the skin was sutured. Control mice (sham) were included in the assays, in which the same pro-
cedure was performed except for LAD occlusion.
Determinationof infarct size
Myocardial infarct size was determined by double staining with Evans Blue/TTC dyes. Animals
were anesthetized and a 0.2% Evans Blue solution was injected into the aorta allowing uni-
formly distribution of the dye. Animals were sacrificed, the hearts frozen, sliced in 1mm ring
sections perpendicular to the LV long axis, and incubated with 0.5% TTC solution for 5 min-
utes. Healthy tissue (blue), area at risk (red), and infarct tissue (pale white) areas were subjected
to morphometric analysis by using the Motic Images Plus software.
Echocardiography
Mouse hearts were visualized by echocardiography, using a ultrasound system (Vivid Q, GE).
During all experiments, mice were anesthetized with 1.5% isoflurane gas, resulting in a heart
rate of approximately 400 beats/min. The chest of the mice were carefully shaved, and warm
ultrasound transmission gel was applied to ensure optimal image quality. Parasternal short-
axis-view images of the heart were recorded n a B-mode to allow M-mode recordings by
positioning the cursor in the parasternal short-axis view perpendicular to the inter-ventricu-
lar septum and posterior wall of the left ventricle. From these recordings, the following
parameters were determined using the on-site software cardiac package: left-ventricle end-
diastolic diameter, left-ventricle end-diastolic volume, ejection fraction, and shortening
fraction.
Histology and immunohistochemistry
Histological and immunohistochemical procedures were performed as previously described
[12].
Immunoblot analysis
Isolation of protein lysates and immunoblots were performed as described [12].
Discontinuous sucrose gradient
Total hearts were isolated and washed twice in ice-cold PBS. Heart tissues were homogenized
in a buffer containing 1 ml of 150 mM sodium carbonate/1 mM EDTA pH 11.0, following 10
times of 5 second bursts in a tissue grinder, combined with 15 seconds sonication, and 1 min
resting on ice. Protein concentration was adjusted to 0.5 mg/ml and mixed with 1 ml of 80%
sucrose in (MES)-buffered saline (MBS). The solution was separated by ultracentrifugation in a
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discontinuous sucrose gradient (40%-30%–5%) in a SW40 rotor (Beckman) at 200,000 × g for
18 h. After centrifugation, 1ml fractions were collected, starting at the upper part of the centri-
fuge tube (lower buoyant density). Samples were separated by SDS-PAGE, and subjected to
immunoblot with anti-Caveolin-3 and anti-NOS2 antibodies.
Statistical analysis
Unless otherwise specified, data are expressed as means SD. Cell culture experiments were per-
formed in triplicate, and conditions were assayed in duplicate on each replicate. Animal experi-
ments were performed in triplicate, and the numbers of animals and replicates are specified in
the text. Whenever comparisons were made with a common control, significance of differences
was tested by analysis of variance followed by Dunnett's modification of the t test. Differences
were considered significant at pb0.05. Error bars represent ± SD.
Results
Ischemia/Reperfusion induces the expression and glycosylation of
EMMPRIN in NOS2 KO mice
IR induces the expression of EMMPRIN in the hearts of WT and NOS2 KO mice, as detected
48 hours after reperfusion (Fig 1). Two fragments of 35 kDa and 50 kDa, corresponding to low
glycosylated (LG) and high glycosylated (HG) EMMPRIN were detected by immunoblot.
However, the ratio betweenHG-EMMPRIN/LG-EMMPRINof 0.4 in WT mice was shifted to
2.8 in NOS2 KO mice, suggesting that in response to IR, glycosylation of EMMPRIN was stim-
ulated in the absence of NO (Fig 1).
Caveolin-3 binds to EMMPRIN in cardiacmyocytes
We found that EMMPRIN co-localizeswith Caveolin-3 in resting HL1B cardiac myocytes, as
detected by confocal microscopy (Fig 2, Control). Incubation of HL1B cells with 100 μM IL-18
induced the expression of EMMPRIN, and a significant inhibition in the binding to Cavelolin-
3 (Fig 2 IL-18). To test whether EMMPRIN glycosylation may play a role, co-incubationwith
100 μM IL-18 plus 10 μM tunicamycin, a pharmacological inhibitor of N-glycosylation of pro-
teins, restored the complex formation back to control cells (Fig 2, IL-18/Tunycamycin). Taken
together, these data suggest that Caveolin-3 binds to LG-EMMPRIN.
IR disrupts the complex Caveolin-3/EMMPRIN in the heart
Caveolin-3 co-localizeswith EMMPRIN in WT and NOS KO mice, as detected by confocal
microscopy of heart sections immunostained with specific antibodies (Fig 3). By contrast, IR
significantly reduced co-localization in NOS2 KO respect to WT mice (Fig 4A). Since IR did
not reduced the levels of Caveolin-3 (Fig 4B), our data suggest that lack of NO in vivo promotes
the dissociation of the complex Caveolin-3/EMMPRIN in response to IR.
The disruptionof the complex Cavolin-3/LG-EMMPRINwas increased in
the absence of NOS2
High glycosylated EMMPRIN oligomerize in the cell surface of many cell types and induces
enzymatic activation of several MMPs. To test whether IR could regulate glycosylation of
EMMPRIN, we first immunoprecipitated heart protein lysates isolated 12h, 24h, and 48 hours
after IR with anti-EMMPRIN antibodies (Fig 5A). EMMPRIN immunoprecipitated extracts
contained similar amounts of Caveolin-3 excepting 48 hours after IR, in which a significant
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reduction of Caveolin-3 was detected in NOS2 KO mice, when compared to the levels found in
WT animals (Fig 5A). On the other hand, in Caveolin-3 immunoprecipitated extracts, mainly
LG-EMMPRIN was present in the hearts of WT mice (Fig 5B, left panels), containing 4 times
more LG-EMMPRIN, compared to the levels found in NOS2 KOs (Fig 5B, right panel), imply-
ing that NO may prevent glycosylation of EMMPRIN, by preserving the complex Caveolin-3/
LG-EMMPRIN in response to IR.
Caveolin-3 exerts its biological function at the time it presents in buoyant membranes. We
show that in NOS2 KO heart protein lysates subjected to discontinuous sucrose gradient frac-
tionation, Caveolin-3 distribution shifted from fractions of lower (buoyant fractions (BF) 2, 3,
4) to higher (non buoyant fractions (NBF) 8, 9, and 10) density (Fig 5C), whereas LG-EMM-
PRIN was mostly concentrated in non-buoyant fractions in NOS2 KO mice. Taken together,
our results suggest that in NOS2 expressing mice, Caveolin-3 may inhibit EMMPRIN glycosyl-
ation by forming a complex in buoyant membranes (Fig 5D).
Fig 1. Ischemia/Reperfusion induces the expression and glycosylation of EMMPRIN in NOS2KOmice.
Immunoblot detection of EMMPRIN inWT and NOS2 KO mice 48 hours after IR. GAPDHwas used as loading
control. HG: high glycosylatedEMMPRIN. LG: Low glycosylated EMMPRIN. (n = 9 mice, mean ± SD *p<0.05WT
HG 48 vs NOS2HG 48. #p<0.05WT LG 48 vs NOS2 LG 48).
doi:10.1371/journal.pone.0162912.g001
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NOS2-induced cardiac protection is mediated by preserving the complex
Caveolin-3/LG-EMMPRIN
To assess whether NOS2 may induce cardiac protection by promoting the binding between
Caveolin-3 and LG-EMMPRIN, we found that in Caveolin-3 KO mice subjected to IR, infarct
sizes (Fig 6A) and left ventricle ejection fractions (LVEF, Fig 6B) were significantly higher than
in Caveolin-3 expressing mice. Interestingly, exogenous administration of the NO donor
DEA-NO in the drinkingwater notably reduced the infarct size in NOS2 KO mice, while
Fig 2. Glycosylated EMMPRIN binds to Caveolin-3 in cardiac cells.Confocal microscopy detection of
Caveolin-3 (Cy-3, red) and EMMPRIN (FITC, green) in HL1B resting (upper panels), incubated 8 hours with
100 μM IL-18 (middle panels), or with 100 μM IL-18 plus 10 μM tunicamycin (lower panels). Colocalizationof both
signals is detected in merged panels (yellow) (n = 9 plus triplicates).Bottom left: Co-localization analysis as
detected by calculation of overlapping correlation coefficient ((n = 9 plus triplicates.*p<0.05 IL-18 vs IL-18
+tunicamycin). Bottom right:Micrographs corresponding to one representative assay in which overlapping green
and red signals are highlighted in white.
doi:10.1371/journal.pone.0162912.g002
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DEA-NO had no effect in Caveolin-3 KO mice under IR (Fig 6C), implying a role of Caveolin-
3 in the cardioprotective effect of NO in response to IR.
To further investigate the contribution of Caveolin-3 on EMMPRIN glycosylation, and the
downstream EMMPRIN-mediated MMP activation, we found that IR induced the levels of
Fig 3. EMMPRIN co-localizeswithCaveolin-3 at the cell surfaceof healthymouse hearts.Confocal
microscopy detection of Caveolin-3 (FITC, green), and EMMPRIN (Cy3, red) in heart sections from healthy WT and
NOSKO mice with specific antibodies. Co-localization (yellow) is shown in themerged panels (n = 9 mice/strain/
triplicated). Bottom left: Co-localization measurement as detected by calculation of overlapping correlation
coefficient ((n = 9 plus triplicates).Bottom right:Micrographs corresponding to one representative assay in which
overlapping green and red signals are highlighted in white.
doi:10.1371/journal.pone.0162912.g003
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Fig 4. Ischemia/Reperfusion disrupts the complex Caveolin-3/EMMPRIN inmouse hearts. (A) Confocal
microscopy detection of Caveolin-3 (FITC, green), and EMMPRIN (Cy3, red) in heart sections fromWT and NOS
KO mice 48 hours after IR with specific antibodies. Co-localization (yellow) is shown in themerged panels (n = 9
mice/strain/triplicate). Bottom left: Co-localization measurement as detected by calculation of overlapping
correlation coefficient ((n = 9 plus triplicates.*p<0.05Control vs NOS2 KO). Bottom right:Micrographs
corresponding to one representative assay in which overlapping green and red signals are highlighted in white. (B)
Left. Immunoblot detection of Caveolin-3 from heart lysates after IR at the times indicated. The expression of
The Complex Caveolin-3/EMMPRIN Is a Target of NO in Cardiac Protection
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MMP-9 in Caveolin-3 KO mice, and exogenous administration of DEA-NO had no significant
effect (Fig 6D). By contrast, in NOS2 KO mice, the NO donor reduced the levels of MMP-9 in
the hearts subjected to IR (Fig 6E upper panel), and the levels of the complex Caveolin-3/
LG-EMMPRIN resulted increased, when compared to those found in NOS2 KO mice (Fig 6E,
middle and lower panels). To further investigate the relevance of MMP enzymatic activity as a
target of NO in cardiac protection, we administered 50mg/Kg doxycycline, a well known tetra-
cycline derivative MMP inhibitor in the drinkingwater of WT, NOS2 KO, and Caveolin-3 KO
mice, 1 week before IR (Fig 6F), detecting that in NOS2 KO and in Caveolin-3 KO mice, the
lesions were significantly reduced. Taken together, our results suggest that NO induces cardiac
protection at least in part, by decreasing ECM degradation through the preservation of the
complex Caveolin-3/LG-EMMPRIN in response to IR.
Discussion
In the current work we show new evidence about the molecularmechanism of NO in cardiac
protection in response to IR. Our data support the hypothesis that NO protects the heart
against IR by preventing ECM degradation. In resting conditions, we show for the first time
that low glycosylated EMMPRIN is bound to Caveolin-3 in WT and NOS2 KO mice, while the
complex was significantly reduced 48 hours after IR in NOS2 KO mice. Exogenous administra-
tion of DEA-NO to NOS2 KO mice rescued in part the WT phenotype, improving [heart func-
tion, and reducing the infarct size and the expression of MMP-9 in response to IR, whereas the
same treatment failed to show any effect in Caveolin-3 KO mice. We suggest that the complex
Caveolin-3/LG-EMMPRIN in NOS2 expressing mice is part of the mechanisms elicited by NO
in cardiac protection.
The expression of EMMPRIN in response to acute myocardial infarction (AMI) has been
described in monocytes/macrophages, in human cardiac myocytes and in animal models of IR
[3, 13, 14]. We and others have found that inhibition of EMMPRIN improves cardiac function
and reduces IR injury [15], but no data so far describes the mechanism that may regulate NO-
mediated inhibition of EMMPRIN activity.
Caveolin proteins play a major role in the pathophysiology of several cardiovascular diseases
[16, 17]. Caveolin-1 has been shown to induce cardiac protection against IR [16, 18–20], and
recent evidences point towards Caveolin-1 as a target to prevent EMMPRIN glycosylation, by
forming a complex with LG-EMMPRIN. Tang et al, have shown that silencing Caveolin-1
expression by siRNA, promoted the shift of HG-CD147/LG-CD147 ratio, from 2.1 in mock-
treated cells, to 6 in Caveolin-1 silenced cells [10]. In the current work, we found a complex
betweenCaveolin-3 and LG-EMMPRIN, suggesting that Caveolin-3 may also inhibit EMM-
PRIN glycosylation in a similar way. To our knowledge, Caveolin-3 protects the heart during
anesthetic-induced cardiac preconditioning [21, 22], and it was recently found the role of
Caveolin-3 in restoring Akt signaling in diabetic rats under IR [23]. Here, we show for the first
time a role of Caveolin-3 in the NO-mediated cardiac protection, by forming a complex with
low glycosylated forms of EMMPRIN.
The activation of MMPs is regulated by HG-EMMPRIN self-aggregation, [24, 25]. Caveo-
lin-1 binds to LG-EMMPRIN and inhibits self aggregation by decreasing glycosylation of
EMMPRIN in several cell types, including macrophage cell cultures [24]. We show here evi-
dence about the role of Caveolin-3 as a target of NO in forming a complex with LG-EMMPRIN
in mouse hearts, and the effect on cardiac function in the presence and in the absence of
GAPDHwas used as loading control. Right. Densitometric analysis of the bands corresponding to the expression
of Caveolin-3 in reference to the levels of GAPDH.
doi:10.1371/journal.pone.0162912.g004
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Fig 5. The complex Caveolin-3/EMMPRIN is disrupted in NOS2KOmice 48 hours after Ischemia/
Reperfusion. (A) Immunoblot (IB) detection of Caveolin-3 from immunoprecipitated extracts (IP) with anti-
EMMPRIN antibody, isolated from heart lysates of mice under IR at the times indicated. Immunoblot
detection of GAPDHwas used as loading control (n = 9 mice, mean ± SD *p<0.05WT vs NOS2 48h). (B)
Upper-Left panel. Immunoblot detection of EMMPRIN from total lysates or immunoprecipitated extracts with
anti-Caveolin-3, and isolated frommouse hearts48 hours after IR. Bottom-left panel. Immunoblot of
Caveolin-3 from the same extracts as above. Upper-right panel. Immunoblot detection of Caveolin-3 from
immunoprecipitated extracts with anti-EMMPRIN and isolated fromWT and NOS2 KO hearts isolated 48
hours after IR. Middle-Right panel. Immunoblot detection of EMMPRIN from immunoprecipitated extracts with
anti-Caveolin-3, from the samemice as before. Lower-Right panel. Immunoblot detection of Caveolin-3 from
total cell lysates and immunoprecipitatedwith anti-Caveolin-3 from the samemice as before (n = 9 mice by
triplicate). (C) Immunoblot detection of Caveolin-3 inWT and NOS2 KO heart proteins separated by
discontinuous sucrose gradient fractionation. Right panel. Densitometric analysis of Caveolin-3 distribution in
WT and NOS2 KO fractions. (n = 3 mice by triplicate,mean ± SD). (D) Immunoblot detection of LG-EMMPRIN
in buoyant (2, 3, 4) and non buoyant (8, 9, and 10) fractions fromWT and NOS2 KO heart proteins separated
by discontinuous sucrose gradient fractionation (n = 3 mice by triplicate,mean ± SD *p<0.05WT vs NOS2
BF; #p<0.05WT vs NOS2 NBF).
doi:10.1371/journal.pone.0162912.g005
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Fig 6. NOS2 inducescardiac protection through the bindingof Caveolin-3with LG-EMMPRIN. (A) Infarct
size ofWT and Caveolin-3 KO hearts48 hours after IR, as detected by double Evans Blue/TTCstaining (n = 9
mice/group; mean ± SD; *p <0.05) (B) LVEF in the samemice as before (mean ± SD; *p <0.05,WT IR vs
Caveolin-3 KO IR). (C) Infarct size 48 hours after IR of NOS2KO andCaveolin-3 KO mice and infusedwith
saline or DEA-NO (n = 9mice/group; mean ± SD; *p <0.05NOS2KO saline vs NOS2KO DEA-NO). (D) Upper
panel. Immunoblot detection of MMP-9 from total protein lysates isolated fromCaveolin-3 KO mice and
Caveolin-3 KO mice treatedwith saline or DEA-NO, 48 hours after IR. The expression of GAPDHwas used as
loading control. (n = 9 mice/group;mean ± SD). (E) Upper-panel. Immunoblot detection of MMP-9 from total
protein lysates isolated fromCaveolin-3 KO, NOS2KO andNOS2KO mouse hearts treatedwith DEA-NO.
Middle-panel. Immunoblot detection of EMMPRIN from immunoprecipitated extracts with anti-Caveolin-3, from
the samemice as before. Lower-panel. Immunoblot of Caveolin-3 from immunoprecipitatedextracts with anti-
EMMPRIN, from the samemice as before (n = 9 mice by triplicated). (F) Infarct size ofWT, NOS2, and
Caveolin-3 KO hearts48 hours after IR, and previously fed with 50mg/kg doxycycline for 1 week (n = 9mice/
group;mean ±SD; *p <0.05NOS2KO vs NOS2KO + DOX. $p <0.05CAV3 KO vs CAV3 KO + DOX).
doi:10.1371/journal.pone.0162912.g006
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Caveolin-3, suggesting that Caveolin-3 prevents HG-EMMPRIN self aggregation, and thereby
induces cardiac protection against IR injury.
We previously described that NO induces transcriptional inhibition of EMMPRIN [3]. To
our knowledge no data regarding protein-protein binding domains betweenCaveolin -1, or -3
and EMMPRIN has been reported, although the Caveolin scaffolding domain (CSD) may be
implicated, since many proteins bind to Caveolin -1, -3 through the CSD, including MMP-13,
MMP-9, and endothelial nitric oxide synthase (eNOS, NOS3) [5, 7, 26], and the use of CSD
peptides of Caveolin-1 and -3 regulate cardiac protection, and inhibit cardiac apoptosis [27].
Further studies focused to define the molecularmechanisms by which NO stabilizes the
complex Caveolin-3/LG-EMMPRIN in response to IR will be required to precisely understand
the molecular signaling pathways triggered by NO in cardiac protection. To this regard, the
S-Nitrosylation of EMMPRIN and/or Caveolin-3, should be explored, since S-Nitrosylation
have been suggested to induce cardioprotection against IR by still unknown mechanisms [28],
and others have demonstrated that EMMPRIN gets S-Nitrosylated in the Golgi apparatus of
endothelial cells [29], suggesting that in cardiac myocytes, NO which is highly produced in
response to IR [3], may also induce S-Nitrosylation of EMMPRIN, as a mechanism of cardiac
protection.
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